06/14/2012 - 12:47pm

Kadmon Pharmaceuticals earlier this month announced that it has launched a new 600 mg/day dose pack of Ribasphere RibaPak (ribavirin, USP), Kadmon's proprietary ribavirin regimen available in a daily, two-pill compliance package for enhanced therapy adherence.

06/14/2012 - 11:24am

Novo Nordisk and the Juvenile Diabetes Research Foundation on Wednesday announced the creation of a joint research and development team to discover and develop novel immunotherapies to prevent, treat and help cure Type 1 diabetes.

06/14/2012 - 11:18am

Stiefel, a GlaxoSmithKline company, on Monday acquired the eczema remedy Toctino (alitretinoin) from Basilea Pharmaceutica.

06/14/2012 - 11:09am

A new Walgreens study released Thursday found that a pharmacist-led training and counseling program for patients receiving an injectable diabetes medication improved medication adherence by 24%.

06/14/2012 - 8:57am

Cellceutix on Wednesday reported that the Food and Drug Administration granted a section 505(b) designation for its Prurisol treatment for psoriasis, which would allow the company to forgo early-stage trials and advance Prurisol into latter-stage clinical trials.

06/13/2012 - 11:50am

As health departments across the country report record numbers of pertussis cases, the results of a new survey of American adults released Wednesday revealed that most parents aren't asking adults close to their infants and young children to get an adult whooping cough booster vaccine, even though they do ask them to follow other basic precautions to safeguard their children's health.

06/13/2012 - 10:51am

Health Net on Tuesday launched a national public service campaign to help increase awareness of prenatal and infant health.

06/13/2012 - 10:07am

Bayer on Tuesday announced that on July 1, Philip Blake will become senior Bayer representative USA, following a common company practice of assigning this oversight role to a senior executive already holding a significant business role or roles within the region.

06/13/2012 - 9:43am

Merck on Wednesday released new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia.